BIGBEAR
PHARMACEUTICAL
Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
AuthenticGuaranteeFast DeliveryPrivacy Based on the durable efficacy and intracranial activity demonstrated in the TRIDENT-1 clinical trial, the next-generation ROS1/TRK inhibitor repotrect···【More】
Update: 23 Jun,2026Source: BigbearViews: 111
When the original drug Repotrectinib, with a monthly treatment cost of tens of thousands of dollars, puts it out of reach for many patients, the gener···【More】
Update: 23 Jun,2026Source: BigbearViews: 102
Repotrectinib, as a next-generation ROS1 and NTRK targeted inhibitor, can effectively overcome multiple resistance mutations to other tyrosine kinase ···【More】
Update: 23 Jun,2026Source: BigbearViews: 115
Ripretinib is a prescription drug for specific advanced cancers, primarily used to treat gastrointestinal stromal tumors (GIST). Its price is affected···【More】
Update: 23 Mar,2026Source: BigbearViews: 117
The price of ripretinib varies depending on the region, specifications, purchase channel, and policies. The reference price for one box typically rang···【More】
Update: 23 Mar,2026Source: BigbearViews: 118
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
